Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Saved in:
| Title: | Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. |
|---|---|
| Authors: | Gardner ER; Clinical Pharmacology Program, SAIC-Frederick, NCI-Frederick, Frederick, MD 21702, USA., Kelly M, Springman E, Lee KJ, Li H, Moore W, Figg WD |
| Source: | Investigational new drugs [Invest New Drugs] 2012 Feb; Vol. 30 (1), pp. 90-7. Date of Electronic Publication: 2010 Sep 07. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 20820910 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gardner+ER%22">Gardner ER</searchLink>; Clinical Pharmacology Program, SAIC-Frederick, NCI-Frederick, Frederick, MD 21702, USA.<br /><searchLink fieldCode="AU" term="%22Kelly+M%22">Kelly M</searchLink><br /><searchLink fieldCode="AU" term="%22Springman+E%22">Springman E</searchLink><br /><searchLink fieldCode="AU" term="%22Lee+KJ%22">Lee KJ</searchLink><br /><searchLink fieldCode="AU" term="%22Li+H%22">Li H</searchLink><br /><searchLink fieldCode="AU" term="%22Moore+W%22">Moore W</searchLink><br /><searchLink fieldCode="AU" term="%22Figg+WD%22">Figg WD</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2012 Feb; Vol. 30 (1), pp. 90-7. <i>Date of Electronic Publication: </i>2010 Sep 07. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=20820910 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10637-010-9520-5 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 90 Titles: – TitleFull: Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gardner ER – PersonEntity: Name: NameFull: Kelly M – PersonEntity: Name: NameFull: Springman E – PersonEntity: Name: NameFull: Lee KJ – PersonEntity: Name: NameFull: Li H – PersonEntity: Name: NameFull: Moore W – PersonEntity: Name: NameFull: Figg WD IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2012 Feb Type: published Y: 2012 Identifiers: – Type: issn-electronic Value: 1573-0646 Numbering: – Type: volume Value: 30 – Type: issue Value: 1 Titles: – TitleFull: Investigational new drugs Type: main |
| ResultId | 1 |
